ASCO 2019 Prostate Cancer - Results from #20

Viewing 21-40 of 83 articles

ASCO 2019: Overall Survival of African-American and Caucasian Men who Received Sipuleucel-T for Metastatic Castration-Resistant Prostate Cancer: Final PROCEED Analysis - Medical Oncologist Perspective

ASCO 2019: Treatment Sequence in Elderly Metastatic Castration-Resistant Prostate Cancer Patients in a Prospective Cohort Study

ASCO 2019: Targeted Next-Generation Sequencing of mCSPC: A Pilot Molecular Analysis in the STAMPEDE Multi-Center Clinical Trial

ASCO 2019: Phase 1 Study of Pasotuxizumab, a PSMA-Targeting Bispecific T cell Engager Immunotherapy for Metastatic Castration-Resistant Prostate Cancer

ASCO 2019: Outcomes of Men with Recurrent M0 Prostate Cancer who Defer Androgen Deprivation Therapy until Metastasis - Medical Oncologist Perspective

ASCO 2019: Targeted Next-Generation Sequencing of Metastatic Castrate-Sensitive Prostate Cancer: A Pilot Molecular Analysis in the STAMPEDE Multi-Center Clinical Trial - Medical Oncologist Perspective

ASCO 2019: Concurrent or Layered Treatment with Radium-223 and Enzalutamide or Abiraterone plus Prednisone/Prednisolone: A Retrospective Study of Real-World Clinical Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer

ASCO 2019: Cardiovascular Morbidity in a Randomized Trial Comparing GnRH-Agonist and Antagonist Among Patients with Advanced Prostate Cancer

ASCO 2019: Pembrolizumab plus Docetaxel and Prednisone in Abiraterone or Enzalutamide-Pretreated Patients with Metastatic Castrate Resistant Prostate Cancer: Cohort B of the Phase 1b/2 KEYNOTE-365 study - Medical Oncologist Perspective

ASCO 2019: Elephant in the Room: Financial Toxicity in Cancer Care

ASCO 2019: From Trials to Treatment: Addressing Disparities in Access to Prostate Cancer Care

ASCO 2019: Taking Patient Preferences to Heart

ASCO 2019: More Than Skin Deep: Investigating Disease Biology, Treatment Response, and Side Effect Differences by Race

ASCO 2019: PSMA: Is Seeing Believing?

ASCO 2019: Overall Survival Results of a Phase III Randomized Trial of Standard-of-Care Therapy with or without Enzalutamide for Metastatic Hormone-Sensitive Prostate Cancer: ENZAMET, an ANZUP-led International Cooperative Group Trial

ASCO 2019: Disparities in Prostate Cancer Across the Cancer Continuum

ASCO 2019: Intensified Up-Front Therapy for Prostate Cancer: The Revolution Continues with ENZAMET

ASCO 2019: Considerations for Systemic Therapy in Optimal Management of Oligometastatic Disease

ASCO 2019: Diagnostic Performance of 18F-DCFPyL in the OSPREY Trial: Imaging in Patients with Known or Suspected Metastatic Prostate Cancer

ASCO 2019: Association of Noninvasive, Radiographic Measurement of PSMA Expression with Response to PSMA-Targeted Radionuclide Therapy

1
2
3
4
5